Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-08-29

FDA Approved: BRIXADI — Supplemental Application (Braeburn Inc.)

View source ↗

Summary

The FDA approved a supplemental application for BRIXADI (buprenorphine) by Braeburn Inc., resulting in updated labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BRIXADI (Buprenorphine)

Snippet

SUPPL AP for BRIXADI (BUPRENORPHINE)